Agreeing upon multiple nephrotoxicity biomarkers at the same time is, of course, an important achievement in its own right. But the larger contribution of the PSTC is that there is now a formal ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and ...

machine learning and AI for data integration and novel biomarker and drug target discoveries. RE-MEND will combine the general population-based studies and clinical studies to define the genetic and ...

The study demonstrated substantial reductions in key biomarkers, including a mean ... drug candidates in its pipeline aimed at treating endocrine conditions. An investor conference call is ...

The study will evaluate alisertib plus investigator’s choice endocrine therapy compared ... evaluate each of these efficacy endpoints within biomarker subgroups to find out whether any biomarker ...

Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

In addition, no differences existed between groups regarding primary treatment and adjuvant endocrine therapy ... coefficients between changes in bone biomarkers and changes in cytokine and ...